Log in to save to my catalogue

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2064782220

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

This phase 3 trial tested inotersen, a modified oligonucleotide that targets
TTR
messenger RNA, in the treatment of hereditary transthyretin amyloidosis, a disease in which misfolded transthyretin proteins are deposited in peripheral nerves and other tissues.

Alternative Titles

Full title

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2064782220

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2064782220

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1716793

How to access this item